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Abstract
Background:  Lymphatic filariasis (LF) is targeted for global elimination. LF elimination
programmes in different countries, including Egypt, are supported financially by national and
international agencies. The national programme in Egypt is based on mass drug administration
(MDA) of an annual dose of a combination of 2 drugs (DEC and albendazole) to all endemic villages.
This study aimed primarily to estimate the Total and Government costs of two rounds of MDA
conducted in Egypt in 2000 and 2001, the average cost per person treated, and the cost share of
the different programme partners.
Methods: The Total costs reflect the overall annual costs of the MDA programme, and we defined
Government costs as those expenditures made by the Egyptian government to develop, implement
and sustain the MDA programmes. We used a generic protocol developed in coordination with the
Emory Lymphatic Filariasis Support Center. Our study was concerned with all costs to the
government, donors and other implementing parties. Cost data were retrospectively gathered
from local, regional and national Ministry of Health and Population records. The total estimates for
each governorate were based on data from a representative district for the governorate; these
were combined with national programme data for a national estimate.
Results: The overall Total and Government costs for treating approximately 1,795,553 individuals
living in all endemic villages in the year 2000 were US $3,181,000 and US $2,412,000, respectively.
In 2001, the number of persons treated increased (29%) and the Total costs were US $3,109,000
while Government costs were US $2,331,000. In 2000, the average Total and Government costs
per treated subject were US $1.77 and $1.34, respectively, however, these costs decreased to US
$1.34 and $1.00, respectively in 2001. The coverage rate was 86.0% in 2000 and it increased to
88.0% in 2001.
Conclusion: The Egyptian government provided 75.8% of all resources, as reflected in the Total
cost estimates, and international agencies contributed the rest. Such data highlight both the
commitment of the Egyptian government and the significance of the contributions of international
bodies toward the LF elimination programme.
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Background
Lymphatic filariasis (LF), also known as elephantiasis is
caused by infection with the threadlike nematode
Wuchereria bancrofti and transmitted by Culex pipiens
mosquitoes; it is known to be endemic in rural areas of
Egypt. Administratively, Egypt consists of 26 governorates
with a population currently estimated at 68 million peo-
ple, more than 60% residing in the densely populated
governorates of the Nile Delta. The disease has a focal dis-
tribution, and it is estimated that currently over 2.5 mil-
lion people are at risk of acquiring W. bancrofti infection.
LF is considered one of the most important vector borne
diseases in Egypt, posing a major public health problem
in 6 governorates in the Nile Delta and the governorates
of Giza and Asiut in Upper Egypt.
In Egypt the Malaria, Filariasis and Leishmaniasis Control
Department of the Ministry of Health and Population
(MOHP) has worked since the 1970s to map and decrease
LF prevalence by focalized treatment initiatives to reduce
transmission. Selective treatment of microfilaremic sub-
jects with a 12-day regimen of diethylcarbamazine (DEC;
6 mg/kg/day) was recommended. In 1996, the MOHP
changed its anti-LF strategy to selective treatment with sin-
gle-dose DEC (6 mg/kg) as it was shown to be equally
effective[1]. In 1997, the World Health Assembly passed a
resolution (50.97) calling for "the elimination of lym-
phatic filariasis as a public health problem." Conse-
quently, the World Health Organization (WHO)
developed a new strategy and initiated a global pro-
gramme for the elimination of lymphatic filariasis as a
public health problem by the year 2020[1].
Egypt was among the first countries to join the WHO glo-
bal efforts. A national programme to eliminate LF as a
public health problem was initiated in the year 2000. In
the years of the focalized control campaign Egypt had
made substantial progress in decreasing microfilaria prev-
alence. Thus, upon joining the global elimination effort,
the programme sought specifically to decrease the micro-
filaria prevalence rates to less than 0.1%. The programme,
which is based on mass drug administration (MDA) of an
annual dose of DEC (6 mg/kg) in combination with
albendazole (400 mg), aims to achieve an MDA coverage
rate of about 80% of the total population of the target
implementation units (IU). The village was chosen as the
IU, and all villages with microfilaria or an antigen preva-
lence rate of 1% or more were included in the LF elimina-
tion programme. The elimination programme, based
within the MOHP, is financially supported also by other
partners within the government, including the Ministries
of Agriculture and Information, and by international
agencies such as WHO (Geneva) and its Eastern Mediter-
ranean Regional Office (EMRO, Cairo), as well as private
donors like GlaxoSmithKline (GSK). The Research and
Training Center on Vectors and Diseases (RTC) at Ain
Shams University (ASU) has been collaborating with the
programme on consultation, training, and surveillance
activities.
The LF elimination programme is managed by the
Malaria, Filariasis and Leishmaniasis Control Department
Headquarters (PHQ) office, supported by a strategic steer-
ing committee. The PHQ office has overall responsibility
for the administration of all MDA activities at the central
level, as well as oversight of activities at the peripheral
(governorate, district and village) levels. District level
filariasis units report data on LF mapping and surveillance
following MDA rounds to the PHQ office. The Ministry of
Agriculture through its guidance units, also at the district
level, participated in local social mobilization activities.
The MOHP infrastructure contains a well-developed net-
work of rural health centers (RHC) to provide health serv-
ices at the village level. RHC physicians, nurses and health
workers in target villages carry out drug distribution and
other MDA related activities. Support for the public edu-
cation and mobilization campaigns came from the Minis-
try of Information that broadcasts materials in various
media at the national level. The Ministry of Religion par-
ticipates on the steering committee. This participation
does not entail any additional financial support. In addi-
tion, the steering committee liaises with local community
leaders to enlist their cooperation in encouraging the gen-
eral public to participate in the MDA campaign. MDA
activities included:
1) Mapping of LF endemic villages based on previous data
and conducting surveys using a rapid format card test for
villages with uncertain LF situation or outdated data. The
population census of the target villages was then updated.
2) Training sessions for physicians and nurses working in
the RHC of the target villages.
3) Social mobilization activities that consisted of meet-
ings with local village leaders, distribution of pamphlets
and posters, short advertising programmes for TV and
radio to create population awareness and facilitate com-
munity participation.
4) House to house drug distribution, where RHC distrib-
utors observed pill consumption.
5) Treatment of adverse reactions to the drugs.
6) Surveillance of residual infection by assessment of
microfilaremia prevalence rates in selected sentinel
villages.Filaria Journal 2005, 4:7 http://www.filariajournal.com/content/4/1/7
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7) Administration of the different programme activities at
different levels.
Supported by a grant from the Bill & Melinda Gates Foun-
dation, the Emory Lymphatic Filariasis Support Center
(Emory LFSC) is coordinating a multi-center cost analysis
study of LF elimination programmes, the first of its kind
in the field of LF. In 2002, the RTC at ASU in collaboration
with the Egyptian MOHP joined the initiative to carry out
a study of two MDA rounds implemented in 2000 and
2001 as part of the LF elimination programme in Egypt.
The primary objectives were to estimate the Total cost and
Government cost of the LF programme in 2000 and 2001,
estimate the average cost per person treated, identify the
programme elements with the greatest contribution to
overall costs, and estimate the cost share of the different
programme partners.
Methods
To achieve the above-mentioned objectives, a generic pro-
tocol was developed and field-tested as part of the nine-
country Emory LFSC study [2]. The protocol was designed
to provide methodological guidance to investigators and
create a systematic approach for country-specific data col-
lection and analysis so that cost estimates would be com-
parable across a variety of settings with different
conditions. The study was concerned with all costs to the
government, donors and other implementing parties. The
medication for the MDA was distributed to the popula-
tion free of charge, as was any medication to treat adverse
reactions. Costs to persons receiving treatment were not
investigated. The estimates for the MDA costs were
obtained through retrospective data collection.
Countries participating in the nine-country Emory LFSC
study went through a process of cost identification and
agreed to cost the following functions: training, mapping,
mobilization and education, drug distribution, adverse
reaction monitoring and treatment, surveillance/labora-
tory, and administration (See Table 1). Two other catego-
ries were added, "LF-non MDA costs" and "Other, non-LF,
non-MDA costs", to help distinguish the resources for the
MDA activities from other LF and MOHP activities. These
two categories of costs were ultimately excluded from the
MDA programme cost calculations.
The costing was divided into the input categories of med-
ications and laboratory supplies (including: medications
for the MDA and adverse reaction treatment, as well as
laboratory supplies), personnel, transport, general sup-
plies, and recurrent and capital costs for facilities and
equipment. Capital costs refer to expenditures for inputs
purchased for use of one or more years. Capital goods
were annualized using a 3% discount rate. These inputs
can be vehicles, facilities or equipment. The calculations
took into account years of useful life of the equipment,
according to Ministry of Finance schedules. When infor-
mation about capital goods was not available, the value of
renting the item was used and considered a recurrent cost.
Recurrent costs are those incurred for goods and services
purchased and used up on a regular basis, such as person-
nel time, most supplies, fuel, etc. Cost information was
gathered for the programme inputs from local, regional
and national MOHP records. This information and
records of recurrent costs provided information on the
percentage of time and resources devoted to the
programme. In addition, programme managers were
interviewed to estimate the percentage of time personnel
devoted to the LF programme.
Drug cost information was provided to the Emory LFSC
and the participating countries by GSK (donated albenda-
zole), and the WHO (purchased DEC). Data on MDA cov-
erage rates to aid in the calculation of cost per person
treated and documentation of personnel salaries and spe-
cial LF incentives came from MOHP district and national
files. The cost of supplies for the MDA, such as drug tab-
lets, ICT cards, adverse reaction medications, etc. was
Table 1: MDA Activities and other cost categories
Activity Definition
Training Instruction of MOH personnel to carry out the administrative and functional activities of the MDA and 
instruction of volunteers to develop skills required for the MDA.
Mapping Testing to establish microfilaria prevalence in communities.
Mobilization and Education Media campaigns and community activities to increase MDA participation.
Drug Distribution Logistic aspects of management of the drugs as well as administration of the drugs to the population.
Adverse Reaction Monitoring Observation and treatment of persons suffering adverse reactions due to the MDA.
Surveillance and Laboratory Tracking of community members in MDA area, laboratory work for testing, case identification, etc.
Administration Supervisory work and paperwork to support the MDA.
LF Non-MDA Costs Costs related to LF, but not the MDA (excluded from cost calculations).
Other Non-LF, Non-MDA Costs MOH costs not at all related to the MDA or to LF (excluded from cost calculations).Filaria Journal 2005, 4:7 http://www.filariajournal.com/content/4/1/7
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collected at the national level. The PHQ office keeps
records of the number of drug tablets and ICT cards dis-
tributed per village. The costs of training and social mobi-
lization initiatives were also estimated from PHQ and
Ministry of Information records. The Ministry of Agricul-
ture provided information on resources it devoted to the
MDA. Estimates for transportation, recurrent and capital
costs were based upon interviews with local personnel at
the district level.
Data were collected from one district in each governorate
and combined with national level cost information about
the number of villages, RHCs, categories and numbers of
personnel in each of these, and aggregated LF incentives
for each district. The districts chosen for the analysis were
chosen at random unless the governorate contained only
one district. In one instance, the governorate contained
two districts and the district chosen was the largest. These
data were used to calculate approximations for other dis-
tricts. Thus, the total estimates for each governorate were
based on data from what was considered a representative
district for the governorate combined with detailed infor-
mation obtained from the national government about
categories and numbers of personnel, their salaries and
any incentives that were offered.
The activities of some MDA partners like Ain Shams Uni-
versity's RTC, which participated in personnel training
and monitoring and evaluation of the MDA, are consid-
ered as part of the MDA but not separately attributed to
these partners since they were funded with central MOHP
monies. In the case of other partners like the Ministry of
Religion and community leaders, obtaining documenta-
tion and monetary quantification of their contributions in
assisting in garnering public support for the MDA was dif-
ficult to do.
This cost analysis sought to estimate a Total programme
cost, accounting for all resources used in carrying out the
programme, including donations of supplies, equipment,
time, etc. This approach is useful in evaluating the alloca-
tion of programme resources and their opportunity costs,
i.e., whether these resources could be used more produc-
tively elsewhere. Government costs are helpful to pro-
gramme managers in looking at actual programme
expenditures and assessing affordability. We defined Gov-
ernment costs as the costs of all inputs paid for by the
Ministry of Health, excluding any direct donations to the
programme. Any donations such as albendazole were
considered part of Total costs, as were any donations
external to the government such as the community or
local or foreign donors. Because the capital costs were
annualized, the cash expenditures described reflect those
incurred in one year for the project.
All costs were prepared in Egyptian pounds (LE), and the
cost of direct supplies donated or provided by different
international agencies were estimated in US dollars (US $)
and converted to equivalent LE amounts. For this paper,
costs are presented in US dollars. The exchange rates used
for costs estimates in 2000 and 2001 were 3.47 and 3.88
LE for US $1.00, respectively. No adjustment was made
for inflation as inflation was negligible in the United
States during the years covered by the analysis. Conver-
sion to U.S. dollars accounted for Egyptian inflation.
Results
Mass Drug Administration Coverage Rate for Calculation 
of Total and Government Costs
In 2000, MDA was implemented in 161 villages in 7 gov-
ernorates. Coverage rates (treated at-risk population
divided by total at-risk population) calculated using the
data collected by RHC distributors ranged among the dif-
ferent governorates from 78.6 to 89.9%. The overall MDA
coverage rate was 86.0% (Table 2). In 2001, the MDA was
carried out in 178 villages in eight governorates with cov-
erage between 85.7 and 95.9%. That year, the estimated
overall MDA coverage rate increased significantly to
88.0% (X2 = 4007, p < 0.0001) (Table 2).
Total and Government costs
The overall Total and Government costs for treating
approximately 1,795,553 individuals living in all
endemic villages covered by the MDA in 2000 were US
$3,181,000 and US $2,412,000, respectively. In 2001, the
number of persons treated increased (29%) to approxi-
mately 2,320,602, and the Total and Government costs
were US $3,109,000 and US $2,331,000, respectively. In
both years, for the Total costs the largest proportion of this
amount was spent for drug distribution (40.9% and
45.9% for 2000 and 2001, respectively), followed by pro-
gramme administration (20.1% and 20.8% for 2000 and
2001, respectively). A similar pattern of expenditure was
also observed for Government costs. Figure 1 shows Gov-
ernment costs of the two MDA rounds (2000 and 2001)
as presented by programme activities.
Generally, there was a high degree of uniformity among
expenditures in all governorates for the different pro-
gramme activities. Note that the costs of mapping, treat-
ment of drug adverse reactions and social mobilization at
the governorate level were relatively low (Figure 2). The
cost of central social mobilization (mainly national TV
and radio broadcasting) was included in PHQ expenses
and accounted for about 24.8% of the central programme
expenses (Figure 2).
The distribution of Total and Government costs by pro-
gramme items including personnel salaries and incen-
tives, equipment and programme facilities, supplies andFilaria Journal 2005, 4:7 http://www.filariajournal.com/content/4/1/7
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transportation showed similar patterns (Figure 3). For
Total costs, the highest expenditure was in the category of
supplies (56.5% and 52.7% for 2000 and 2001, respec-
tively) followed by personnel (27.0% and 30.1% for 2000
and 2001, respectively). The lowest programme expendi-
ture was for transportation since almost all villages were
served by local RHCs. Thus for the most part teams
distributing drugs worked in the same villages and did not
move very far. The majority of transportation that took
place in the MDA programme was for sending drugs from
MOHP central storage to RHCs and for supervision by the
district director.
Comparison of MDA costs for governorates covered by 
MDA in the 2 years
There was a wide range (9%-122%) in the increases of per-
sons treated in the governorates with at risk populations
during the 2001 MDA compared to 2000. The greatest
increase was in Dakahlia (122%) followed by the gover-
norates of Kafr El Sheikh (81%) and Menofia (50%). The
Table 2: MDA coverage rates for 2000 and 2001
Governorate 2000 2001 % increase 
in treated 
population
No. of 
districts
No. of 
Treated 
villages
*Treated 
population
MDA 
coverage 
(%)
No. of 
districts
No. of 
Treated 
villages
Treated 
population
MDA 
coverage 
(%)
Qalyubia 7 68 818,488 82.9 7 68 890,967 85.7 9
Menofia 4 24 190,024 88.8 4 25 284,786 88.4 50
Sharkia 6 32 272,722 84.4 6 32 324,762 89.1 19
K. El Sheikh 1 1 18,200 78.6 1 2 32,972 95.9 81
Dakahlia 1 24 192,063 89.9 1 36 426,588 95.4 122
Gharbia 2 2 51,782 87.7 2 2 57,638 90.9 11
Giza 4 10 216,274 80.8 4 11 237,679 85.7 10
Assiut 2 2 65,210 87.6
Total 25 161 1,795,553 86.0 27 178 2,320,602 88.0 29
*Treated population is defined as the number of persons who ingested the drugs, based on family forms filled by drug distributors.
Government costs of the different programme activities during the MDA in 2000 and 2001 Figure 1
Government costs of the different programme activities during the MDA in 2000 and 2001.
0
200
400
600
800
1000
1200
Training Mapping S. Mobilization Drug D. Adverse R. Surveillance Administration
x 1000 $US
 2000
 2001Filaria Journal 2005, 4:7 http://www.filariajournal.com/content/4/1/7
Page 6 of 11
(page number not for citation purposes)
MDA Total cost share % for programme activities as presented for the Programme Head Quarter (PHQ) and a representative  governorate in 2000 Figure 2
MDA Total cost share % for programme activities as presented for the Programme Head Quarter (PHQ) and a representative 
governorate in 2000.
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overall increase in treated population in 2001 was 29%
(Table 2). In terms of cost, the overall programme Total
and Government costs as expressed in Egyptian pounds
increased 9.6% and 7.8%, respectively. However, these
costs as expressed in US dollars decreased 2% and 3% due
to the re-evaluation of the pound against the dollar (Table
3). The overall cost of personnel increased 13.2%, partic-
ularly in Dakahlia (73.6%), Kafr El Sheikh (29.6%) and
Menofia (14.7%) governorates (data not shown). None-
theless, the overall Total and Government costs for sup-
plies; equipment and programme facilities; and
transportation did not change significantly (<10%). How-
ever, in 2001 a significant increase in supplies caused
Government costs to rise in Dakahlia (77.2%), Kafr El
Sheikh (36.8%) and Menofia (37.3%) governorates,
whereas the costs for equipment and programme facili-
ties, and transportation increased only in Dakahlia gover-
norate (43.7% and 38.6%, respectively; data not shown).
Average cost per treated subject
In 2000, the average Total and Government costs per
treated subject were US $1.77 and US $1.34, respectively.
In 2001, however, these costs decreased to US $1.34 and
US $1.00, respectively. The ranges for average Total costs
per treated person among the different governorates for
2000 and 2001 were US $1.15–1.96 and US $1.02–1.28,
respectively (Table 3). A similar pattern was observed for
the Government costs per person treated among the dif-
ferent governorates (Table 3).
2000 and 2001 MDA Total and Government costs distributed by programme inputs Figure 3
2000 and 2001 MDA Total and Government costs distributed by programme inputs.
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Contribution of different partners to the elimination 
programme
As stated above the Total costs reflect the overall annual
costs of the MDA programme. We defined as Government
costs those expenditures made by the Egyptian govern-
ment to develop and sustain the MDA programmes. All
donations, including community donations were
excluded from the Government cost calculations. In Egypt
the overall Total costs were US $3,181,000 in 2000 and
US $3,109,000 in 2001. After excluding donations for
medication (DEC and albendazole), ICT cards and the
cost of developing TV video advertisements, Government
costs were US $2,412,000 in 2000 and US $2,331,000 in
2001.
Figure 4 shows the relative contribution of the different
programme partners in 2000. WHO provided DEC and
the cost of producing TV video advertisements which
accounted for 6.7% of the total programme expenses; GSK
donated albendazole, 16%; EMRO provided ICT cards,
1.5%; the Ministry of Agriculture provided 2.5% in kind
through the use of agriculture guidance units, the Ministry
of Information provided the cost of national TV broad-
casting, 27%; and the remaining 46.3% was from the
MOHP resources. Overall, the government of Egypt con-
tributed 75.8% of the Total costs. A similar pattern of con-
tributions by the same partners was observed for 2001
(data are not shown).
Table 3: Comparison Between Government, Total Costs and Cost per Person Treated in 2000 and 2001
Total Government and Total Costs and Cost per Person Treated
2000 2001
Costs 
(US$)
Cost per person treated 
(US$)
Costs 
(US$)
Cost per person treated 
(US$)
Programme 
Level
Government 
Cost
Total Cost Government 
Cost
Total Cost Government 
Cost
Total Cost Government 
Cost
Total Cost
Governorate 
level
Qalyubia 696,000 949,000 0.85 1.16 653,000 913,000 0.73 1.03
Menofia 264,000 320,000 1.39 1.68 275,000 358,000 0.97 1.26
Sharkia 325,000 405,000 1.19 1.48 308,000 403,000 0.95 1.24
K. Sheikh 30,000 36,000 1.65 1.96 32,000 42,000 0.98 1.28
Dakahlia 220,000 281,000 1.14 1.46 322,000 452,000 0.75 1.06
Gharbia 59,000 74,000 1.14 1.44 56,000 73,000 0.97 1.27
Giza 181,000 249,000 0.84 1.15 172,000 241,000 0.7 1.02
National level
PHQ 637,000 867,000 0.35 0.48 513,000 627,000 0.22 0.27
TOTAL 2,412,000 3,181,000 1.34 1.77 2,331,000 3,109,000 1.00 1.34
*Assiut is not included in Table 3 as MDA commenced in 2001.
Contributions of national and international partners to the  Egyptian LF elimination programme in 2000 Figure 4
Contributions of national and international partners to the 
Egyptian LF elimination programme in 2000.
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Contribution of MOHP to MDA cost in relation to the 
overall MOHP expenditures in the studied districts
Table 4 summarizes the contribution of the MOHP to the
cost of MDA (2000) in relation to the MOHP total
expenditure for endemic diseases in the studied districts as
presented by governorate. In general, there was a close
range from 9% for Qalyubia governorate to 12% for K.
Sheikh governorate. The overall MOHP contribution to
the cost of this MDA round accounted for 10% of the total
MOHP expenditure for endemic diseases. Data for 2001
(not shown) were similar to these obtained for 2000.
Discussion
The present work is part of a multi-center study using a
generic protocol to analyze the Total and Government
costs of LF elimination programmes in different settings
with diverse field and programmematic conditions. This
study sought to estimate and analyze the Total costs of
Egypt's LF programme for the first two MDA rounds
implemented in 2000 and 2001. Data were retrospectively
collected for each year separately. In analyzing the data,
we distinguished between Total and Government costs
that provide different but complementary information.
We defined as Government costs those expenditures made
by the government of Egypt to develop, implement and
sustain the MDA programmes. All donations, including
community donations were excluded from the Govern-
ment cost calculations.
Analysis of Total costs, restricted to MDA activities,
revealed that the average cost per treated subject decreased
in 2001 (US $1.34) from 2000 (US $1.77). This is largely
the result of economies of scale, in that the programme
depended on the MOHP's well articulated health system
infrastructure and use of the same capital items (RHC
buildings, laboratory equipment, etc) to treat and serve a
larger number of persons. In support of this conclusion it
should be noted that although the number of treated
subjects increased (29%) in 2001, the average costs per
treated person decreased (28.5%), and the cost of person-
nel and other inputs increased by only 13%. Currency
exchange rate changes tended to magnify the observed
decrease in cost. But even normalizing the 2001 exchange
to equal that in 2000, yielded a cost per treated subject of
$1.50 that is still less than the 2000 figure of $1.77. The
exchange rate in 2001 (3.88 LE for US $1.00) was higher
than in 2000 (3.47 LE for US 1.00).
The average per-treatment Total cost for implementing the
first annual MDA round (US $1.77) was comparable to
that reported for southern India in 2002 (US $1.49)[3],
based on an annual DEC-ivermectin regimen, and higher
than that calculated in Tanzania in 1996 (US $0.70)[4],
based on a semi-annual DEC mass treatment. Govern-
ment costs for the two years of MDA were US $1.34 in
2000 and US $1.00 in 2001. Nonetheless, this informa-
tion is intended, not really as a comparison, but more to
help to contextualize the results of the Egypt study. A
number of elements could partially account for the cost
difference among programmes in Egypt, India and Tanza-
nia, including, the added cost of either albendazole or
ivermectin and the fact that different measures may have
been used in the analyses, and different time periods ana-
lyzed. The Emory LFSC multi-country cost analysis
project, which included the costing of the Egypt MDA pro-
gramme in 2001 and 2002, reported here, was developed
to facilitate comparability between country programmes
by establishing definitions for inputs and activity
categories.
The MDA implementation units (IUs) consisted primarily
of rural agricultural villages with comparable configura-
tions and structures of health systems but different popu-
lation sizes, and a few semi-urbanized towns. The
similarity among IUs may explain the observed high
degree of uniformity in the structure of costs for the differ-
ent programme activities among endemic governorates.
Indeed, overall governorate Total and Government costs
scale up proportionally to the size of treated populations
(Table 3).
Table 4: MOHP contribution to cost of MDA (2000) in relation to MOHP total endemic diseases expenditure
Region MOHP* expenditure Cost of MDA (MOHP) %
Qalyubia $3,868,000 $357,000 9
Menofia $1,252,000 $132,000 11
Sharkia $1,514,000 $162,000 11
K. Sheikh $126,000 $15,000 12
Dakahlia $1,057,000 $111,000 11
Gharbia $292,000 $30,000 10
Giza $963,000 $93,000 10
Total $9,072,000 $900,000 10
*Estimated MOHP expenditure, in US dollars, on endemic diseases in target district presented by governorate.Filaria Journal 2005, 4:7 http://www.filariajournal.com/content/4/1/7
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We noted that the costs of mapping, treatment of drug
adverse reactions and social mobilization at the periph-
eral levels (village, district and governorate) were
relatively low (Figure 2). No doubt that the low mapping
cost was due to the fact that most LF endemic villages were
already known to MOHP from previous data, and the use
of the card test was restricted to mapping the relatively few
villages with an uncertain LF situation or outdated data.
Adverse events after the first MDA were uncommon and
mostly of mild to moderate severity, the most frequently
observed being fever, headache, and myalgia. These symp-
toms, believed to be mainly due to dying worms, usually
resolved within two to three days[5]. Adverse reactions
following the second round of MDA were greatly reduced
compared to those observed following the first round.
These observations would greatly explain the low cost of
the treatment of drug adverse reactions.
The two MDA rounds studied, implemented in 2000 and
2001, were considered very successful, as the overall MDA
coverage rates reached 86.0% and 88.0%, respectively
(Table 2). While high treatment coverage is not always
found in MDA programmes elsewhere [6-8] in the current
programme different social mobilization approaches were
implemented at different central and peripheral levels to
secure high MDA coverage. Estimated costs of social
mobilization at the village and district levels were quite
low (about 2–3% of the total governorate expenditure)
but is worth noting that the cost of one critical social
mobilization activity, involvement of religious leaders at
the village level, could not be quantified in the current
study. A Moslem leader, for instance, would dedicate a
few minutes of his speech (usually about 30 minutes
long) at Friday prayers on two to three occasions to
emphasize the importance of the MDA programme and to
encourage audiences to take the treatment; on the other
hand, the estimated central cost for social mobilization
(national TV and radio broadcastings) was quantifiable
and quite high (Figure 4), accounting for about 27% of
the total programme expenditure.
The number of persons treated increased 29% in 2001
over 2000. This was the result of normal population
growth (estimated country growth rate 2.1%) in all vil-
lages, of adding new implementation units particularly in
Dakahlia governorate (12 villages), and of including
small hamlets (satellites to villages) as in the case of
Menofia governorate. In Kafr El Sheikh governorate, only
one village was added in 2001 but this resulted in a dou-
bling of the number of persons treated (Table 2). When
Total and Government costs were compared between the
two years, the costs of personnel increased 13.2%. For the
most part, this reflects participation of more manpower
(physicians, nurses and other health workers) particularly
in Dakahlia and Kafr El Sheikh governorates or increased
person work days to cover the newly added satellite vil-
lages as in the governorate of Menofia. Generally, how-
ever, the Total and Government costs for supplies did not
change significantly in the governorates with the excep-
tion of Dakahlia, Kafr El Sheikh and Menofia. Costs of
equipment and programme facilities increased in the gov-
ernorate of Dakahlia only, as a result of using more capital
items and RHC facilities in 2001. Similarly, the cost of
transportation increased in Dakahlia only, as a conse-
quence of the costs of supervising the MDA in more
implementation units.
We also analyzed the MOHP contribution to the Govern-
ment cost of MDA (2000) in relation to the total MOHP
expenditure for endemic diseases in the studied districts
and grouped them by governorate. The analysis showed
that the cost of MDA represents a relatively small cost bur-
den (10%) on the MOHP budget for endemic diseases.
The LF elimination programme was financially supported
by several national and international partners. Our data
(Figure 4) indicated that national agencies contributed
about 75.8% (cash or in kind) of the Total costs highlight-
ing the commitment of the Egyptian government toward
the LF elimination programme. This does not minimize
the significance of the contributions of international bod-
ies. GSK provided all albendazole tablets free of charge,
WHO (Geneva) purchased DEC tablets, EMRO supplied
card tests through a contribution from the Arab Fund for
Economic and Social Development.
Based on MOHP data before the initiation of the LF elim-
ination programme, about 314 villages had a history of LF
endemicity [9]. Currently, 178 villages, with >1% LF prev-
alence, are included in the national elimination pro-
gramme and covered by multiple MDA rounds. Many of
the remaining villages are believed to have infection rates
<1%, based on data acquired before 1990. However, map-
ping activities undertaken in certain governorates (e.g.
Dakahlia governorate) in 2000 and 2001 revealed that 12
villages have >1% LF prevalence rates and were therefore
added to the MDA programme. In this context, the MOHP
is now required to map the remaining previously endemic
villages and to initiate a supplemental MDA programme
to include any village found to have prevalence rates of
1% or more. This remains an essential step prior to certi-
fying Egypt as country free of LF. Therefore, data from the
present study are of great importance to MOHP decision
makers for developing a supplemental programme expan-
sion, with a realistic budget estimate and for raising funds
essential for its implementation.Publish with BioMed Central    and   every 
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Conclusion
The present study estimated the overall Total and Govern-
ment costs of MDA in LF-endemic villages in the Nile
Delta and the governorates of Giza and Asiut in Upper
Egypt. Approximately 1,795,553 individuals, living in 161
villages in 7 governorates, were treated by MDA in the year
2000 with a coverage rate of 86.0%. The overall Total and
Government costs for MDA that year were US $3,181,000
and US $2,412,000, respectively. Average Total and Gov-
ernment costs per treated subject and person at risk in
2000 were US $1.77 and US $1.34, respectively. In 2001,
while the number of persons treated increased (29%) and
the coverage rate increased to 88.0%, the Total and Gov-
ernment costs decreased to US $3,109,000 and US
$2,331,000, respectively. Consequently, the average Total
and Government costs per treated subject and per person
at risk decreased to US $1.34 and US $1.00, respectively.
National agencies of Egypt contributed 75.8% of the Total
costs, a fact highlighting the commitment of the Egyptian
government toward the LF elimination programme but
not minimizing the significance of the contributions of
international bodies, such as WHO, EMRO, GSK and the
Arab Fund for Economic and Social Development.
The results of this study set the stage for the MOHP to ini-
tiate a supplemental MDA programme expansion, esti-
mate a realistic budget and raise essential funds for its
implementation. The objectives of the supplemental pro-
gramme are to map villages with a previous history of LF,
not included in the current programme, and ensure cover-
age of eligible villages with needed MDA rounds. This
action is necessary prior to certifying Egypt as a country
free of LF.
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